The first approved non-CD19 cell therapy was ldecabtagene vicleucel, created against B cell maturation antigen (BCMA), which has shown effectiveness in treating multiple myeloma (Ali et al., 2016; Brudno et al., 2018). The gene discussed is TNFRSF17; the disease is AL amyloidosis.